HEALTH

PARSIPPANY, N.J. — Global spending on medicines will reach nearly $1.1 trillion by 2015, according to a new study by market research firm IMS Health.

EMERYVILLE, Calif. — Clif Bar on Monday introduced Meet the Moment, a social site where people can share inspiring athletic photos and stories of accomplishment.

As part of the site launch, at MeettheMoment.com, Clif Bar will award three people who upload the most inspirational and creative moments by July 31 an opportunity to pursue their dream adventure. Each winner will select the adventure of their choice (up to a maximum value of $12,000).

SILVER SPRING, Md. — A Food and Drug Administration panel will discuss findings in a clinical trial that has raised concerns about the safety and efficacy of Abbott's cholesterol-lowering drug when it’s combined with similar drugs, according to an FDA announcement.

ALLEGAN, Mich. — Perrigo on Monday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for over-the-counter ranitidine 150 (regular and cool mint), a generic version of Zantac 150.

Zantac 150 has annual sales of approximately $110 million, as measured by SymphonyIRI Group, Perrigo reported.

WATSONVILLE, Calif. — Nordic Naturals on Tuesday announced the company has earned certification from NSF International, verifying that its new Leadership in Energy and Environmental Design corporate headquarters complies with good manufacturing practices.

"NSF's exceptional commitment to public safety is in line with our own values and Nordic Naturals' mission to deliver pure, safe and effective omega oils worldwide,” stated Joar Opheim, Nordic CEO.

WASHINGTON — More than 25% of American women are focused on and proactive about their health and well-being, according to a national study released last week by “Life…supplemented.”

WASHINGTON — The Food and Drug Administration is convening its Nonprescription Drugs Advisory Committee Tuesday and Wednesday to debate mandating weight-based dosing for pediatric medicines containing acetaminophen on the Drug Facts label, as well as the potential expansion of dosing instructions to incorporate children under the age of 2 years old, according to material posted online by the FDA on Friday.

SAN DIEGO — Amylin Pharmaceuticals filed suit against Eli Lilly in federal court Monday concerning an agreement between the latter and German drug maker Boehringer Ingelheim to develop drugs for diabetes.

In a complaint filed in the U.S. District Court for the Southern District of California, Amylin said Lilly engaged in unlawful and anticompetitive activity in its development and commercialization agreement with BI for Tradjenta (linagliptin), an orally administered Type 2 diabetes drug that the Food and Drug Administration recently approved.